
Black Opal Ventures is a venture capital firm that invests in early-phase companies using deep tech and frontier technology to improve healthcare, focusing on the intersection of healthcare and technology.
35% of their portfolio is in Healthcare. Deal activity increased 33% year-over-year (4 deals in the last 12 months). Average disclosed round size is $49.3M (across 19 rounds with reported amounts).
Portfolio
19
Fund Size
$63M
Top Stage
Series A
Last 12 Mo
4
Team
Dr. Carina Tyrrell, MB BChir, MPH
Founder & Managing Director Select BOV Companies: FlyteHealth, Optellum, Empatica, Conceivabe, Oath, GV20, Chamber
Eileen Tanghal, MBA
Founder & Managing Director Select BOV Companies: Hyro, Outpace, TigerGraph, Blaze, AuthMind, Parasail Select Pre-BOV Companies: Cerebras Systems, Twist Bioscience, Sequans, Paragraf
Eve Castel, CFA
Venture Partner
Franco Danesi, MBA
Venture Partner
Joseph Jeong, PhD
Venture Partner
Hanna Edgren
Chief of Staff & Venture Analyst
Justin Craib-Cox, CFA
Head of Investments
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| Series A | $45M | Mar 2026 | |
| Unknown | — | Feb 2026 | |
| Series A | $60M | Feb 2026 | |
| Unknown | $200M | Jan 2026 | |
| Series B | $54.4M | Oct 2025 | |
| Series A | $10.5M | Aug 2025 | |
| Seed | $8.5M | Apr 2025 | |
| Series A | $10.5M | Jan 2025 | |
| OOath Surgical | Series A | $24M | Jan 2025 |
| Seed | $19.3M | Jan 2025 | |
| Series A | $10.5M | Jan 2025 | |
| Series B | — | Dec 2024 | |
| Series B | $144M | Aug 2024 | |
| Series A | $24M | Jan 2024 | |
| OOutpace Bio | Series B | $144M | Jan 2024 |
| Series B | $20M | May 2023 | |
| Series B | — | Nov 2022 | |
| Series A | $14M | Sep 2022 | |
| Series A | $60M | — | |
| OOath Surgical | Seed | $10M | — |
| Series B | $33M | — | |
| TTen63 Therapeutics | Unknown | $45M | — |
| Series B | — | — |
Top Co-Investors
Last updated: 20 October 2026